secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kinnate Biopharma Inc. (—)
CIK:        0001797768
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001193125-24-085548
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA completes acquisition of Kinnate for $2.5879/share plus CVR; trading halted
--------------------------------------------------------------------------------

- 38.3M shares (81%) tendered in offer; all conditions satisfied; merger effective April 3, 2024.
- Shareholders receive $2.5879 cash per share plus one non-transferable CVR per share.
- All Kinnate directors and officers resigned; Owen Hughes (XOMA) becomes sole director and officer.
- Kinnate requested Nasdaq to suspend trading and delist shares; expects deregistration on Form 15.
- Outstanding stock options and RSUs vested and cancelled in exchange for cash and/or CVRs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/d651169d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-085548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer